Home
 /
Papers
 /
Genetics
 /
A shared DNA-repeat toxicity threshold, reached somatically at cell-type-specific rates, unites cortical and striatal neurodegeneration in Huntington’s disease
Preprint
Open access
V1
Top 1% · Validated by QED

A shared DNA-repeat toxicity threshold, reached somatically at cell-type-specific rates, unites cortical and striatal…

Seva Kashin, Won-Seok Lee, Tara M. McDonald +10 more
December 2025
 ·
bioRxiv
 ·
DOI 
10.64898/2025.12.09.688862
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Genetics this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

Resolving a decades-long debate, this paper proves that cortical vulnerability in HD is cell-autonomous—driven by neuron-intrinsic somatic CAG expansion rates—overturning connectivity-based models and converging both cortex and striatum onto a single therapeutic strategy.

Author perspective

What is the most important insight, discovery, or finding from your paper that you would like other scientists to know?
“

In Huntington’s disease (HD), the pathologies in the two major affected brain areas – the cerebral cortex and the striatum –were long thought to have different mechanisms, with one as a secondary consequence of the other due to the synaptic connections between them. In this work, experiments revealed that neurodegeneration in both brain areas actually has the same mechanism – and that this mechanism is cell-autonomous and involves somatic expansion of the disease-causing DNA repeat (a CAG repeat in the Huntington (HTT) gene) – beyond a high threshold of about 150 CAGs, which is shared by cortical and striatal neurons. The experiments also taught us that, although neurodegeneration in these two brain areas has the same biological propellant (somatic expansion of the CAG repeat beyond the 150 threshold), it has different downstream sequelae in the two brain areas. These experimental data show that a simple, unifying model explains the distinct neurodegenerative pathologies in two different brain areas in HD.

”
Steven McCarroll

QED claims analysis

Summary

Cortical and striatal neurodegeneration in Huntington's disease arise from analogous cell-autonomous mechanisms in which somatic expansion of each neuron's own HTT CAG-repeat tract beyond a shared toxicity threshold of approximately 150 CAGs initiates pathological gene expression changes and subsequent cell death, with apparent differences in timing and severity between brain regions resulting from profound variation in somatic expansion rates across molecularly distinct neuronal types rather than from differences in cellular sensitivity to HTT toxicity or secondary effects of corticostriatal connectivity.

See full analysis
Main Claim 1 –

Cortical pyramidal neurons uniquely show >100 CAG somatic expansion

Supporting evidence

  • Pyramidal subtypes vary widely in neurons exceeding 100 CAGs
  • Molecular identity outweighs cortical area in determining expansion rates
  • Cortical neurons show two-phase expansion accelerating beyond 90 CAGs
Main Claim 2 –

Pathological transcription begins at ~150 CAGs in cortical neurons

Supporting evidence

  • Phase C changes are cortex-consistent but differ from striatum
  • Phase C erodes pyramidal neuron identity-defining gene expression
  • Very long expansions trigger Phase D de-repression of developmental genes
Main Claim 3 –

Higher somatic expansion rates predict greater pyramidal neuron loss

Abstract

Huntington’s disease (HD) affects two major brain areas – the striatum and cerebral cortex – in ways that differ in timing, severity, and gene-expression changes. For these reasons, and because many cortical neurons project axons to the affected striatal neurons, striatal and cortical atrophy have long been proposed to have distinct mechanisms, with one potentially a secondary consequence of the other.

In the striatum, we recently found that neurons degenerate asynchronously as their own huntingtin (HTT) gene CAG-repeat tracts, typically inherited at 40-50 CAGs, expand somatically beyond 150 CAGs. To ask whether a similar or different dynamic affects the cerebral cortex, we analyzed HTT CAG repeats and genome-wide RNA expression together in more than 130,000 nuclei from 12 cortical areas of brain donors with HD.

The resulting data revealed that cortical and striatal neurodegeneration in fact result from analogous sequences of cell-autonomous events, each instructed by somatic expansion of a neuron’s own HTT CAG repeat. Analyses revealed that somatic expansion beyond a high toxicity threshold (of about 150 CAGs) is necessary and sufficient to initiate pathological changes; that this pathogenicity length threshold is shared by striatal and cortical projection neurons of all types; and that cortical area, cortical layer, and axonal projections play only incidental roles, as proxies for the true driver: profound (up to 50-fold) variation among types and subtypes of pyramidal neurons in the likelihood of reaching the 150-CAG toxicity threshold in a human lifetime. These results also suggest that containing somatic DNA-repeat expansion below this high toxicity threshold would protect both brain areas in HD.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?